Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
  • Press releases
  • Corporate reports
  • Facts, products, pipeline
  • Photo library
  • Broadcast Centre
  • Events calendar
  • Media contacts
• Investors

You are here

• Home

• Media

Here you will find our corporate press releases, details on upcoming events and other useful information for business and financial media.

• Latest news collapse

  • 29 October 2009 AstraZeneca PLC Third Quarter & Nine Months Results 2009

    Strong business performance has been driven by good operating execution bolstered by revenue upsides from Toprol-XL and H1N1 vaccine sales. Core EPS target for the year has been increased and progress has been made on the pipeline with the approval of ONGLYZA(TM), the European submission for Brilinta and new external collaborations, tempered by the disappointing news on Zactima.

  • 28 October 2009 AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC

    AstraZeneca announced today that it has withdrawn the regulatory submissions for the use of ZACTIMA (vandetanib) 100mg in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) from the US FDA and the European Medicines Agency (EMEA). The applications were submitted to regulatory agencies in June 2009.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Financial results collapse

  Third Quarter & Nine Months results 2009 announced Thursday, 29 October
  2009.

  • View details of the event
  • View financial calendar

  Photo & video library collapse

  • Here you can download pictures from our photo library
  • Broadcast footage of AstraZeneca products and activities is available from our Broadcast Centre (requires registration)

• Key Facts collapse

  • We are a world leading pharmaceutical company with a world-class biologics capability.
  • We are active in over 100 countries with a growing presence in important emerging markets including China; corporate office in London, UK; and major R&D sites in Sweden, the UK and the US.
  • We employ over 65,000 people (51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia).
  • Alongside our commitment to competitiveness and performance, we continue to be led by our core values to achieve sustainable success.
  • More facts about AstraZeneca

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

Not signed in

Page tools

• Print
• Bookmark this page

Share price